AMR

McGill Antimicrobial Resistance Centre to tackle one of humanity’s greatest threats

Retrieved on: 
Monday, September 19, 2022

MONTREAL, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Antimicrobial resistance (AMR) is a global scale threat to human life and economic prosperity.

Key Points: 
  • MONTREAL, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Antimicrobial resistance (AMR) is a global scale threat to human life and economic prosperity.
  • With the launch of the new McGill Antimicrobial Resistance (AMR) Centre, a partnership between McGill University and the Research Institute of the McGill University Health Centre (RI-MUHC), Montreal is becoming a powerhouse in understanding and preventing AMR.
  • The McGill University Health Centre (MUHC) Foundation raises funds to support excellence in patient care, research and teaching at the McGill University Health Centre, one of the top university hospitals in Canada.
  • www.muhcfoundation.com
    The Research Institute of the McGill University Health Centre (RI-MUHC) is a world-renowned biomedical and healthcare research centre.

Bugworks Research Inc. and Cytecare Cancer Hospitals announce collaboration to accelerate the development of cutting-edge Immuno-oncology therapies

Retrieved on: 
Monday, September 19, 2022

BENGALURU, India, Sept. 19, 2022 /PRNewswire/ -- Bugworks Research Inc., a clinical stage biopharmaceutical company, and Cytecare Cancer Hospitals today announced the launch of a first-of-its-kind collaboration.

Key Points: 
  • BENGALURU, India, Sept. 19, 2022 /PRNewswire/ -- Bugworks Research Inc., a clinical stage biopharmaceutical company, and Cytecare Cancer Hospitals today announced the launch of a first-of-its-kind collaboration.
  • Bugworks develops best-in-class, novel therapies for cancer and infectious diseases & has set up a dedicated research center within Cytecare, which is committed to excellence in treating cancer patients.
  • Bugworks' approach, in collaboration with Cytecare Hospitals, offers new avenues to increase the percentage of patients who would benefit from these life-saving immunotherapies.
  • Cytecare launched its flagship center, Cytecare Cancer Hospitals, a 150-bed organ-site focused cancer hospital, in November 2016 at Yelahanka, Bengaluru.

Bugworks Research Inc. and Cytecare Cancer Hospitals announce collaboration to accelerate the development of cutting-edge Immuno-oncology therapies

Retrieved on: 
Monday, September 19, 2022

BENGALURU, India, Sept. 19, 2022 /PRNewswire/ -- Bugworks Research Inc., a clinical stage biopharmaceutical company, and Cytecare Cancer Hospitals today announced the launch of a first-of-its-kind collaboration.

Key Points: 
  • BENGALURU, India, Sept. 19, 2022 /PRNewswire/ -- Bugworks Research Inc., a clinical stage biopharmaceutical company, and Cytecare Cancer Hospitals today announced the launch of a first-of-its-kind collaboration.
  • Bugworks develops best-in-class, novel therapies for cancer and infectious diseases & has set up a dedicated research center within Cytecare, which is committed to excellence in treating cancer patients.
  • Bugworks' approach, in collaboration with Cytecare Hospitals, offers new avenues to increase the percentage of patients who would benefit from these life-saving immunotherapies.
  • Cytecare launched its flagship center, Cytecare Cancer Hospitals, a 150-bed organ-site focused cancer hospital, in November 2016 at Yelahanka, Bengaluru.

ResGreen Announces Enhanced Simulation Feature for BotWay Software

Retrieved on: 
Friday, September 16, 2022

SHELBY TOWNSHIP, MI, Sept. 16, 2022 (GLOBE NEWSWIRE) -- ResGreen Group International, Inc. (OTC Pink: RGGI), a next-gen mobile robot and software solutions company, announced today it has enhanced its simulation capabilities for its leading BotWay interoperable software.

Key Points: 
  • SHELBY TOWNSHIP, MI, Sept. 16, 2022 (GLOBE NEWSWIRE) -- ResGreen Group International, Inc. (OTC Pink: RGGI), a next-gen mobile robot and software solutions company, announced today it has enhanced its simulation capabilities for its leading BotWay interoperable software.
  • The simulation can determine the number of vehicles needed, route configuration, charging station placement, traffic management, triggering and more.
  • ResGreen engineers use simulation to detect potential congestion issues, configure vehicle routes and station locations and test traffic stops.
  • Because the simulation feature is built into our BotWay software, we offer it at a fraction of the cost of other companies.

Locus Robotics Passes One Billion Units Picked

Retrieved on: 
Thursday, September 15, 2022

WILMINGTON, Mass., Sept. 15, 2022 /PRNewswire/ -- Locus Robotics (www.locusrobotics.com), the market leader in autonomous mobile robots (AMR) for fulfillment warehouses, today announced they have surpassed the One Billion units picked milestone. This new achievement was attained just 59 days after Locus registered 900 million units picked.

Key Points: 
  • WILMINGTON, Mass., Sept. 15, 2022 /PRNewswire/ -- Locus Robotics ( www.locusrobotics.com ), the market leader in autonomous mobile robots (AMR) for fulfillment warehouses, today announced they have surpassed the One Billion units picked milestone.
  • This new achievement was attained just 59 days after Locus registered 900 million units picked.
  • "Reaching our One Billion pick milestone underscores the critical business value that Locus's proven technology brings to our customers around the world, every day," said Rick Faulk, CEO, Locus Robotics.
  • "One billion picks is an incredible milestone and is testament to Locus Robotics' innovation and vision over the past few years."

Locus Robotics Passes One Billion Units Picked

Retrieved on: 
Thursday, September 15, 2022

WILMINGTON, Mass., Sept. 15, 2022 /PRNewswire/ -- Locus Robotics (www.locusrobotics.com), the market leader in autonomous mobile robots (AMR) for fulfillment warehouses, today announced they have surpassed the One Billion units picked milestone. This new achievement was attained just 59 days after Locus registered 900 million units picked.

Key Points: 
  • WILMINGTON, Mass., Sept. 15, 2022 /PRNewswire/ -- Locus Robotics ( www.locusrobotics.com ), the market leader in autonomous mobile robots (AMR) for fulfillment warehouses, today announced they have surpassed the One Billion units picked milestone.
  • This new achievement was attained just 59 days after Locus registered 900 million units picked.
  • "Reaching our One Billion pick milestone underscores the critical business value that Locus's proven technology brings to our customers around the world, every day," said Rick Faulk, CEO, Locus Robotics.
  • "One billion picks is an incredible milestone and is testament to Locus Robotics' innovation and vision over the past few years."

AI & Smart Automation Conference to Unlock Power of Artificial Intelligence September 29 in Columbus

Retrieved on: 
Wednesday, September 14, 2022

Manufacturers interested in unleashing the power of artificial intelligence in their operations can learn about the latest innovations and best applications at the AI & Smart Automation Conference on September 29 in Columbus, Ohio.

Key Points: 
  • Manufacturers interested in unleashing the power of artificial intelligence in their operations can learn about the latest innovations and best applications at the AI & Smart Automation Conference on September 29 in Columbus, Ohio.
  • Organized by the Association for Advancing Automation (A3), the one-day powerhouse briefing features experts from Siemens, Procter & Gamble, NVIDIA, RAPID Robotics, Landing AI, and more.
  • Register now for access to conference sessions focused on cutting-edge trends, business strategies, workforce requirements, and tips on how to build the right culture for success.
  • Every day, we are pounded with messages about how AI will solve all your production problems, said Robert Huschka, A3s vice president of education strategies.

Ouster Introduces 3D Industrial Sensor Suite for High-Volume Material Handling Applications

Retrieved on: 
Wednesday, September 14, 2022

Ouster is poised to become the default choice for industrial automation with the launch of our industrial sensor suite alongside upcoming chip releases, software, and industrial safety certifications, said Ouster CEO Angus Pacala.

Key Points: 
  • Ouster is poised to become the default choice for industrial automation with the launch of our industrial sensor suite alongside upcoming chip releases, software, and industrial safety certifications, said Ouster CEO Angus Pacala.
  • With this product line, we aim to capture a significant share of the $1 billion market for industrial lidar sensors as customers see the immense benefits of converting from analog 2D industrial lidar to our digital 3D lidar suite.
  • For more information on Ousters industrial sensor suite, read more or reach out to an Ouster representative at [email protected].
  • Ouster (NYSE: OUST) is building a safer and more sustainable future through its high-resolution digital lidar sensors for the automotive, industrial, smart infrastructure, and robotics industries.

Antibody-Mediated Rejection Epidemiology Forecasts, 2019-2032 - Focus on United States, Germany, Spain, Italy, France, United Kingdom, and Japan - ResearchAndMarkets.com

Retrieved on: 
Monday, September 12, 2022

This Antibody-Mediated Rejection (AMR) - Epidemiology Forecast-2032 report delivers an in-depth understanding of the Antibody-Mediated Rejection, historical and forecasted epidemiology as well as the Antibody-Mediated Rejection trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Key Points: 
  • This Antibody-Mediated Rejection (AMR) - Epidemiology Forecast-2032 report delivers an in-depth understanding of the Antibody-Mediated Rejection, historical and forecasted epidemiology as well as the Antibody-Mediated Rejection trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
  • The epidemiology section provides insights about the historical and current Antibody-Mediated Rejection patient pool and forecasted trends for individual seven major countries.
  • The epidemiology segment also provides the Antibody-Mediated Rejection epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • What is the historical Antibody-Mediated Rejection patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?

International Robot Safety Conference Returns In-Person; Critical Topics Relevant Amid Highest Quarter for Robot Sales in North America

Retrieved on: 
Monday, September 12, 2022

The conference and trade show will cover key issues in robot safety and provide an in-depth overview of current industry standards related to industrial robotics, including conventional, collaborative, and mobile robot systems.

Key Points: 
  • The conference and trade show will cover key issues in robot safety and provide an in-depth overview of current industry standards related to industrial robotics, including conventional, collaborative, and mobile robot systems.
  • Registration includes access to educational conference sessions featuring more than 40 safety professionals, and the exhibit hall expo on Wednesday.
  • As a result, the International Robot Safety Conference is more important than ever for integrators, manufacturers, and end-users who need to make sure their knowledge of robot safety and risk assessment is current.
  • IRSC will help businesses reduce risk by ensuring personnel are familiar with robot and machine safety as well as current robot safety standards.